A B S T R A C T The myopathy associated with vitamin D deficiency was examined in vitamin D-deficient and vitamin D-supplemented rats. When compared with either vitamin D-supplemented ad lib. or pair-fed rats, weight gain and muscle mass were decreased in vitamin D-deficient hypocalcemic animals. With the exception of a modest decrease in muscle creatine phosphate levels, muscle composition was unchanged by vitamin D deficiency. Muscle protein turnover rates were determined in both in vivo and in vitro studies and demonstrated that myofibrillar protein degradation was increased in vitamin D deficiency. Normal growth rates could be maintained be feeding the rats vitamin D-deficient diets containing 1.6% calcium, which maintained plasma calcium within the normal range. In addition to its role in maintaining plasma calcium, vitamin D-supplemented rats had significantly higher levels of the anabolic hormone insulin. Vitamin D supplementation may affect muscle protein turnover by preventing hypocalcemia, as well as directly stimulating insulin secretion, rather than by a direct effect within skeletal muscle.
INTRODUCTION
The association between vitamin D deficiency states and muscle abnormalities has been noted frequently (1) (2) (3) (4) . Vitamin D deficiency is associated with a proximal myopathy and histologic evidence of muscle fiber atrophy, which rapidly improve after the administration of vitamin D3 or its metabolites (5) (6) (7) (8) . The mechanism through which vitamin D metabolites acts is still uncertain. Within any tissue, protein turnover is de-termined by both rates of protein synthesis and degradation so that alterations in either or both processes could be responsible for the effects of vitamin D within muscle. Among the factors known to regulate muscle protein turnover are food intake (9) , various hormones (10) , and muscle work (11) . Recently, in in vitro studies, calcium has also been shown to have a direct effect on muscle protein turnover rates (12, 13) . Vitamin D administration increases plasma calcium levels, improves force generation by muscle, affects the secretion of other hormones, and is associated with increased food intake (5, (14) (15) (16) . In addition, a direct anabolic effect within muscle has been suggested for one vitamin D metabolite. Two 25 (OH)D3 (7) . In a second, preliminary study, epitrochlearis muscle preparations taken from uremic rats were incubated for 1 h with or without 25(OH)D3 added to the media. Addition of 25(OH)D3 led to decreased rates of alanine and glutamine release suggesting that 25(OH)D3 decreased protein degradation in vitro (8) . Unfortunately, the methods utilized in both studies are not entirely satisfactory for the assessment of protein turnover within muscle. Quantitation of protein turnover requires a marker amino acid, which is neither metabolized nor synthesized within that tissue (10) . Leucine, alanine, and glutamine do not meet these requirements, since muscle is a major site of leucine oxidation (17) ; alanine and glu-tamine are formed within muscle and their release from muscle does not accurately reflect protein degradation (18) . This paper reports our attempts to delineate the effects of vitamin D deficiency on skeletal muscle protein turnover. We measured growth and muscle composition in young, vitamin D-deficient rats before and after supplementation with cholecalciferol. Independent rates of muscle protein synthesis and degradation were assessed during in vitro perfusion studies in rats using a well-characterized, physiologic muscle perfusion system. Phenylalanine, an amino acid that is not metabolized or synthesized in muscle, was used as the marker amino acid. Myofibrillar degradation rates were also assessed both in vitro and in vivo by measuring the rate of release of the amino acid NT-methylhistidine (MH). MH is formed by the posttranslational methylation of specific histidyl residues within actin and myosin (19) . During myofibrillar degradation the MH released is not reutilized for synthesis but is rapidly and quantitatively excreted in urine (20) . Several studies and critical reviews have demonstrated that MH release accurately reflects muscle degradation in the rat (21) (22) (23) .
Finally, the importance of calcium as a moderator of muscle protein turnover was assessed through the use of diets designed to maintain normocalcemia in the face of vitamin D deficiency. Several days before the collection of 24-h urine samples, the rats were weighed and placed in individual metabolic cages. This was done because we have consistently noted higher rates of urinary MH excretion in rats during the first 24 h after being transferred to individual cages (24) . After the rats had acclimated, urine was collected (HCI preservative) for 24 h before vitamin D3 supplementation and for 24-h periods up to 5 d thereafter. At the end of each day's urine collection, the rats were weighed and the cage bottoms washed with distilled water to insure complete urine collection. Urine volume was measured and aliquots of urine were frozen at -20°C for later determination of MH and creatinine levels.
METHODS
When pair-feeding and food intake studies were conducted, rats were placed in cages with fine mesh bottoms. Each day the quantity of food remaining the previous day removed and carefully weighed and a known quantity of food was placed in the cages. The amount of food consumed by each vitamin D-deficient rat was then given to its pairfed, vitamin D-supplemented mate. There was no attempt to correct for small amounts of food dropped through the bottom of the cage but visual inspection suggested that food wastage was no different between different groups of rats.
At various times after the administration of vitamin D3 or vehicle, the rats were anesthetized with pentobarbital and either utilized for hemicorpus perfusion studies or killed to determine carcass weights, muscle composition, plasma MH, calcium, phosphorus, insulin, and creatinine levels. Carcass, visceral, and gastrointestinal weights were determined by weighing. Tissue muscle from gastrocnemius was frozen in situ using a Wollenberger clamp, cooled in liquid nitrogen and stored at -80°C. Gastrocnemius muscle was pulverized using a mortar and pestle cooled in liquid nitrogen. Samples of muscle powder were used for determination of RNA-phosphorus, DNA-phosphorus, protein, ATP, and creatine phosphate.
Hemicorpus perfusion was performed according to the method of Jefferson et al. (25) . The rats were heparinized and anesthetized with sodium pentobarbital. Through an abdominal incision, the major arteries, veins, and viscera were ligated. The chest was opened, the aorta cannulated, the perfusion begun, and the vena cava severed. (27) . Protein concentration was determined by the biuret method (28) using crystalline bovine albumin as standard. RNA-phosphorus and DNA-phosphorus were determined by the method of Manchester and Harris (29) . ATP and creatine phosphate levels were determined enzymatically (30, 31) . Serum 25(OH)D3 levels were determined by high-pressure liquid chromatography (32 (Table I) . After the development of hypocalcemia, it was always possible to stimulate weight gain by a single injection of cholecalciferol (Fig. 2) . This was associated with a significant increase in the efficiency of weight gain, which increased from 0.34 to 0.53 gram weight gain per gram food intake (P < 0.001). Because these rats were studied at a younger age than rats begun on vitamin D-deficient diets at weaning, weight gain per gram food intake was higher in both vitamin D-deficient and vitamin D-supplemented groups. Within each experiment, efficiency of weight gain always improved after cholecalciferol therapy. Rats raised on 1.6% calcium diets maintained normal growth rates as long as they remained normocalcemic (Fig. 3) . After the development of hypocalcemia at 61 d of life, growth rates declined (data not presented).
With vitamin D-deficient diets containing 0.8% calcium, plasma calcium levels decreased over time in the vitamin D-deficient rats. The development of hypocalcemia was inversely related to the percent dietary calcium, requiring -3 wk on 0.8% calcium diet, in rats started on diet at weaning and in rats obtained with lactating dams at 7 d of age (Table I) . Phosphorus levels are also presented and are not significantly different between vitamin D-deficient and -treated groups.
When the rat dams were started on the 0.8% calcium diets, their pups were normocalcemic until 22 (Table II) . Unsupplemented rats demonstrated reduced urinary calcium/creatinine ratios (0.27±0.019 mg calcium/mg creatinine), while still normocalcemic 5 (9.8 mg/dl). The urinary calcium/creatinine ratio decreased further to 0.09 with the development of hypocalcemia (Table II) . In rats fed a vitamin D-deficient diet containing 1.6% calcium, plasma calcium levels were normal, while the urinary calcium/creatinine ratio was as low as that seen in hypocalcemic rats i mg/dl (Table II) . This suggested that these rats were also 6.9^w tO3vitamin D deficient. To insure that our rats were indeed vitamin D deficient, all experiments on muscle 9.5 ± 0.3 composition, protein synthesis, and protein degradation were done with animals on diets for 32 d or longer. 40 45 Treatment of hypocalcemic vitamin D-deficient rats rapidly led to increased weight gain but after the inithe growth of vitamin tial 1-4-d period there was no further catch-up growth re fed a vitamin D-and weights tended to parallel those of chronically 0.45% P. At 22 d of treated animals (Fig. 2) . To determine whether the that same diet or one alcemia was observed increase in weight also reflected increased muscle the two groups were mass, the carcass weight/body weight ratios were deints are the means of termined in vitamin D-deficient and -treated animals, ±1 SEM.
along with muscle protein, RNA, DNA, ATP, and cre- (7) Rats were weaned onto the indicated diets. Cholecalciferol was administered after rats became vitamin D deficient. Plasma samples were obtained at killing several days later. Mean±SE (n). I P < 0.02 vs. -cholecalciferol. assessed in vitro in the perfused hemicorpus. Release rates, calculated as nanomoles per hour per gram hemicorpus were determined 24 and 48 h after vitamin D administration. In rats fed 0.8% calcium diet, there was a 30% decrease in the rate of MH release from hemicorpus preparations 24 or 48 h after treatment with cholecalciferol (P < 0.02, Table IV ). Since the muscle concentration of free MH was not significantly changed during the perfusion (3.7±0.3 nmol/g at 1 h and 3.4±0.5 nmol/g at 3 h), the MH that appeared in the perfusate must reflect ongoing actomyosin degradation during this 2-h period.
Using phenylalanine as a marker amino acid, rates of synthesis and degradation of total muscle protein within the hemicorpus system were measured. After treatment with cholecalciferol, synthesis rates increased and degradation decreased. Although these changes were suggestive, they did not reach statistical significance for either process (P = 0.14) (Table IV) . However, in determining net anabolic response to vitamin D supplementation, a small increase in synthesis (10.6 nmol phenylalamine/h per g) and a small decrease in degradation (9.1 nmol/h per g) would be additive (Table IV) . There are 175 tsmol of phenylalanine/g muscle protein (25) , 200 mg protein/g muscle, and the proportion of muscle to body weight is the same as muscle to hemicorpus weight (34) . Since the carcass/body weight ratios were the same for vitamin D-deficient and vitamin D-supplemented rats, all tissues probably grow proportionately. Therefore the +19.7 nmol/h per g net increase in protein anabolism seen after vitamin D supplementation equals an increase in growth rate of 2.0 g/d per 150 g rat, [(+19.7 nmol phenylalanine/h per g muscle) X (24 h) X (150 g rat) X (0.2 g protein/g muscle)/(175,mol phenylalanine/g protein)]. This value is close to the increase in the weight gain observed in our vitamin D-supplemented animals (Fig. 1) .
Plasma insulin levels were determined in both vitamin D-deficient and vitamin D-supplemented rats receiving 0.8 and 1.6% calcium diets. Plasma 25(OH)D3 levels were equal in both vitamin D-supplemented groups and all vitamin D-deficient rats had undetectable 25(OH)D3 in their plasma. Plasma insulin levels rose successively with both dietary calcium and vitamin D treatment (Table VI) . When analyzed by twoway analysis of variance, only vitamin D treatment could be shown to be significantly related to the increase in plasma insulin levels.
DISCUSSION
In our studies, decreased weight gain was not directly associated with vitamin D deficiency, but rather with the development of hypocalcemia. By the time significant weight differences were apparent between vitamin D-deficient and vitamin D-supplemented pairfed rats, our vitamin D-deficient rats were hypocalcemic. Our pair-feeding studies show that differences in weight gain between vitamin D-deficient and treated rats are in part related to decreased intake but also associated with the development of vitamin D deficiency and hypocalcemia. Prevention of hypocalcemia, either by increasing the percentage of dietary calcium as in our study or, by feeding lactose (35) to increase intestinal calcium absorption, effectively maintains growth rates, normal rates of MH release, and eliminates any effect of cholecalciferol administration on stimulation of weight gain.
Vitamin D deficiency probably developed at the same time in our animals fed 0.8%, compared to 1.6%, calcium diets for two reasons. First, urinary calcium/ creatinine ratios were decreased in both groups of rats irrespective of plasma calcium, while normocalcemic animals with only modest plasma levels of 25(OH)D3 When vitamin D was given to hypocalcemic rats, weight gain and muscle mass rapidly increased. We tried to determine whether this was due to increased rates of protein synthesis or decreased degradation by measuring these rates in either in vivo or in vitro studies. We were able to demonstrate significant decreases in myofibrillar protein degradation rates by measuring MH release and MH/creatinine excretion ratios in vitro and in vivo, respectively. We also measured the incorporation and release of phenylalanine by the hemicorpus after both acute and chronic vitamin D administration. Our results suggest both increased phenylalanine incorporation into gastrocnemius muscle protein and decreased phenylalanine release from the hemicorpus. Our inability to demonstrate statistically significant changes in individual rates of protein synthesis or degradation in our phenylalanine studies is understandable because differences in growth rates before and after vitamin D are small when translated into percent changes in phenylalanine uptake or release for a 2-h perfusion period. Calculations based on the net increase in muscle protein anabolism can, however, account for most of the increased growth seen after vitamin D administration.
In other studies comparing phenylalanine and MH release we have been able to demonstrate larger changes in MH release in comparison to phenylalanine release in response to various stimuli such as fasting, refeeding, or addition of cycloheximide to the perfusion media (37) . We hypothesized that this is due to the fact that phenylalanine is present within all body proteins while MH is restricted to actin and myosin only. Individual proteins are degraded at different rates. The release of phenylalanine and MH from protein should therefore be viewed as two measures of protein degradation, which while qualitatively similar, cannot be compared quantitatively.
We have recently demonstrated that up to 40% of a rat's daily MH production is derived from gastrointestinal tissue (34) . Although the gastrointestinal tract may be the source of some of the MH produced in vivo, it cannot explain the changes in MHI release seen in vitro in our eviscerated preparation. Calculating changes in growth rates based upon MH release rates determined in vitro suggest that the changes in degradation could be an important component of the improved weight gain seen after vitamin D supplementation.
In a previous report, Birge and Haddad (7) What is responsible for decreased myofibrillar degradation rates after vitamin D supplementation? Our original hypothesis was that vitamin D had a direct anabolic effect within muscle but our ability to maintain normal weight gain in normocalcemic vitamin Ddeficient rats suggests that this is not so. Our pair-feeding studies and the increased weight gain per gram of food intake rule out a primary role for diminished food intake.
Decreased intracellular ATP levels have been suiggested as a possible cause of decreased protein anabolism (7) . In agreement with other reports in humans (3) and chicks (14) we found normal ATP levels along with mildly decreased creatine phosphate levels in vitamin D-deficient animals. Young et al. (3) feel that the modest decreases in creatine phosphate levels seen in vitamin D deficiency could not explain the myopathy seen in this condition.
Vitamin D deficiency is associated with both hyperparathyroidism and metabolic acidosis (1, 39, 40 (45) had previously reported that specific receptors exist in the pancreas for 1,25(OH)2D3 and proposed that this metabolite acts directly on pancreatic a-cells to increase calcium uptake, thus stimulating insulin release in vivo. Our data also support a role for vitamin D exclusive of extracellular calcium in the control of plasma insulin levels. If this schema is correct and administration of vitamin D acts to increase free cytosolic calcium levels within the pancreas, this could explain reports in which either 1,25-dihydroxycholecalciferol, la-hydroxycholecalciferol, or pharmacological amounts of 25(OH)D3 effectively improve the myopathy of chronic renal failure, a condition in which 25(OH)D3 levels may be normal (46) . In summary, the administration of vitamin D to vitamin D-deficient rats leads to improved muscle protein anabolism and an increase in muscle mass and weight gain. A major effect of vitamin D administration on muscle is due to a decrease in the rate of myofibrillar protein degradation, which can be demonstrated both in vivo and in vitro. Vitamin D appears to act indirectly, either by restoring extracellular calcium levels to normal, by stimulating pancreatic se-
